MARINO JAMES J 4

What Happened James J. Marino, a director of Celldex Therapeutics (CLDX), was granted a derivative award for 26,000 shares on 2026-06-25. The Form 4 records the transaction as an award/grant (code A) with an acquisition price of $0.00 — this represents a stock option grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-25; filing date: 2026-06-29 (filed timely).
• Transaction type/code: Award/Grant (A); derivative security (option) for 26,000 shares; reported acquisition price $0.00.
• Footnote: F1 — Option granted pursuant to the Issuer’s 2021 Omnibus Equity Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No exercise or sale occurred — this is a grant of rights to acquire shares in the future, not an immediate purchase or sale.

Context This filing documents a compensation-related option grant to a director. Option grants are common as part of executive/director pay and typically vest over time and may require a future exercise payment to convert into common shares. Because this was a grant (not a sale), it should be viewed as compensation rather than a direct buy/sell signal.